Human mitochondrial dna polymorphisms, haplogroups, associations with physiological conditions, and genotyping arrays

• US 20050123913A1
• Filed: 08/30/2002
• Published: 06/09/2005
• Est. Priority Date: 08/30/2001
• Status: Abandoned Application

• Current Assignee: Emory University
• Original Assignee: Emory University
• Inventors: Hosseini, Seyed, Lott, Marie, Mishmar, Dan, Ruiz-Pesini, Eduardo, Wallace, Douglas C.
• Application Number:
  US10/488,618
• Publication Number:
  US 20050123913A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6888 for detection or identification of organisms
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/172 Haplotypes
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

This invention provides human mtDNA polymorphisms that are diagnostic of all the major human haplogroups and methods of diagnosing those haplogroups and selected subhaplogroups. This invention also provides methods for identifying evolutionarily significant mitochondrial DNA genes, nucleotide alleles, and amino acid alleles. Evolutionarily significant genes and alleles are identified using one or two populations of a single species. The process of identifying evolutionarily significant nucleotide alleles involves identifying evolutionarily significant genes and then evolutionarily significant nucleotide alleles in those genes, and identifying evolutionarily significant amino acid alleles involves identifying amino acids encoded by all nonsynonymous alleles. Synonymous codings of the nucleotide alleles encoding evolutionarily significant amino acid alleles of this invention are equivalent to the evolutionarily significant amino acid alleles disclosed herein and are included within the scope of this invention. Synonymous codings include alleles at neighboring nucleotide loci that are within the same codon. This invention also provides methods for associating haplogroups and evolutionarily significant nucleotide and amino acid alleles with predispositions to physiological conditions. Methods for diagnosing predisposition to LHON, and methods for diagnosing increased likelihood of developing blindness, centenaria, and increased longevity that are not dependent on the geographical location of the individual being diagnosed are provided herein. Diagnosis of an individual with a predisposition to an energy metabolism-related physiological condition is dependent on the geographic region of the individual. Physiological conditions diagnosable by the methods of this invention include healthy conditions and pathological conditions. Physiological conditions that are associated with haplogroups and with alleles provided by this invention include energetic imbalance, metabolic disease, abnormal energy metabolism, abnormal temperature regulation, abnormal oxidative phosphorylation, abnormal electron transport, obesity, amount of body fat, diabetes, hypertension, and cardiovascular disease.

Claims

1-81. -81. (canceled)

82. A method for diagnosing a haplogroup of a human comprising:

a) providing a sample comprising mitochondrial nucleic acid from said human; and

b) identifying, in said sample, the presence or absence of at least one nucleotide allele diagnostic of a haplogroup, said at least one nucleotide allele selected from the group consisting of alleles listed in Table 3.

83. The method of claim 82 wherein said haplogroup is selected from the group consisting of:

a) haplogroup A wherein method step b) comprises identifying in said sample at least one nucleotide allele selected from the group consisting of 663G, 16290T, and 16319A;

b) haplogroup C wherein method step b) comprises identifying in said sample at least one nucleotide allele selected from the group consisting of 3552C, 4715G, 7196A, 8584A, 9545G, 13263G, 14318C, and 16327T;

c) haplogroup D wherein method step b) comprises identifying in said sample at least one nucleotide allele selected from the group consisting of 4883T, 5178A, 8414T, 14668T, and 15487T;

d) haplogroup E wherein method step b) comprises identifying in said sample the nucleotide allele 16227G;

e) haplogroup F wherein method step b) comprises identifying in said sample at least one nucleotide allele selected from the group consisting of 12406A and 16304C;

f) haplogroup G wherein method step b) comprises identifying in said sample at least one nucleotide allele selected from the group consisting of 4833G, 8200C, and 16017C;

g) haplogroup H wherein method step b) comprises identifying in said sample at least one nucleotide allele selected from the group consisting of 2706A and 7028C;

h) haplogroup I wherein method step b) comprises identifying in said sample at least one nucleotide allele selected from the group consisting of 4529T, 10034C, and 16391A; and

i) haplogroup J wherein method step b) comprises identifying in said sample at least one nucleotide allele selected from the group consisting of 295T, 12612G, 13708A, and 16069T.

84. The method of claim 82 wherein said haplogroup is haplogroup B and wherein method step b) comprises:

1) identifying in said sample nucleotide allele 16189C;

2) identifying in said sample the absence of a nucleotide allele selected from the group consisting of 1719A, 3516G, 6221C, 14470C, and 16278T; and

identifying in said sample the absence of a nucleotide allele selected from the group consisting of 1888A, 4216C, 4917G, 8697A, 10463C, 11251G, 11467G, 12308G, 12372A, 12633T, 13104G, 13368A, 14070G, 14905A, 15452A, 15607G, 15928A, 16126C, 16163C, 16186T, 16249C, and 16294T.

85. The method of claim 82 wherein said haplogroup is selected from the group consisting of:

a) haplogroup T wherein method step b) comprises identifying in said sample at least one nucleotide allele selected from the group consisting of 11812G, 12633T, 14233G, 16163C, 16186T, 1888A, 4917G, 8697A, 10463C, 13368A, 14905A, 15607G, 15928A, and 16294T;

b) haplogroup U wherein method step b) comprises identifying in said sample at least one nucleotide allele selected from the group consisting of 3197C, 4646C, 7768G, 9055A, 11332T, 13104G, 14070G, 15907G, 16051G, 16129C, 16172C, 16219G, 16249C, 16270T, 16311T, 16318T, 16343G, and 16356C;

c) haplogroup V wherein method step b) comprises identifying in said sample at least one nucleotide allele selected from the group consisting of 72C, 4580A, and 15904T;

d) haplogroup W wherein method step b) comprises identifying in said sample at least one nucleotide allele selected from the group consisting of 204C, 207A, 1243C, 5046A, 5460A, 8994A, 11947G, 15884C, and 16292T;

e) haplogroup X wherein method step b) comprises identifying in said sample at least one nucleotide allele selected from the group consisting of 1719A, 3516G, 6221C, and 14470C;

f) haplogroup Y wherein method step b) comprises identifying in said sample at least one nucleotide allele selected from the group consisting of 7933G, 8392A, 16231C, and 16266T; and

g) haplogroup Z wherein method step b) comprises identifying in said sample at least one nucleotide allele selected from the group consisting of 11078G, 16185T, and 16260T.

86. The method of claim 82 wherein said haplogroup is selected from the group consisting of:

a) haplogroup L0 wherein method step b) comprises identifying in said sample at least one nucleotide allele selected from the group consisting of 4586C, 9818T, and 8113A;

b) haplogroup L1 wherein method step b) comprises identifying in said sample at least one nucleotide allele selected from the group consisting of 825A, 2758A, 2885C, 7146G, 8468T, 8655T, 10688A, 10810C, and 13105G;

c) haplogroup L2 wherein method step b) comprises identifying in said sample at least one nucleotide allele selected from the group consisting of 2416C, 2758G, 8206A, 9221G, 11944C, and 16390G; and

d) haplogroup L3 wherein method step b) comprises identifying in said sample at least one nucleotide allele selected from the group consisting of 10819G, 14212C, 8618C, 10086C, 16362C, 10398A, and 16124C.

87. The method of claim 82 wherein said identifying step is performed using an array comprising two or more isolated nucleic acid molecules attached to a substrate at a known location, each molecule having a length of about 7 to about 30 nucleotides, each molecule comprising a sequence identical with a portion of SEQ ID NO:

1 containing at least one nucleotide allele at a locus selected from the group of loci consisting of those listed in column 1 of Table 3.

88. A method for identifying an evolutionarily significant gene, said method comprising:

a) providing a first set of nucleotide sequences comprising nucleic acid sequences of at least one allelic gene located in the mitochondrial genome or portion thereof from a first population;

b) providing a second set of nucleotide sequences comprising nucleic acid sequences of the corresponding at least one allelic gene located in the mitochondrial genome or portion thereof from a second population;

c) performing neutrality analysis, comprising comparing said first set to said second set to generate a data set; and

d) analyzing said data set to identify an evolutionarily significant gene.

89. The method of claim 88 wherein said first population and/or said second population comprises at least one subpopulation, said subpopulation being selected from the group consisting of macro-haplogroup, haplogroup, sub-haplogroup, and individual.

90. The method of claim 88 wherein said second set of nucleotide sequences comprises at least 100 nucleotides identical to a portion of SEQ ID NO:

2.

91. The method of claim 88 wherein said evolutionarily significant gene is a mitochondrial gene selected from the group consisting of ND1, ND2, ND3, ND4, ND5, ND6, Cytb, COI, COII, COIII, ATP6, and ATP8.

92. The method of claim 88 also comprising identifying at least one evolutionarily significant nucleotide allele by identifying a sequence difference between said first and second nucleotide sequences.

93. The method of claim 92 also comprising identifying an evolutionarily significant amino acid allele by determining the evolutionarily significant amino acid allele encoded by the codon comprising said evolutionarily significant nucleotide allele.

94. The method of claim 93 also comprising identifying an amino acid allele diagnostic of a predisposition to a physiological condition by using as said first population, individuals having said physiological condition, and using as the second population, individuals not having said physiological condition.

95. A method for diagnosing an individual with a predisposition to a selected physiological condition comprising:

a) providing a sample comprising mitochondrial nucleic acid molecule from an individual;

b) providing information identifying the geographic region in which said individual resides;

c) providing information identifying a set of haplogroups native to said geographic region;

d) determining the haplogroup of said individual from said sample;

e) comparing said haplogroup of said individual to said set of haplogroups native to said geographic region; and

f) diagnosing said individual with a predisposition to said selected physiological condition if said haplogroup of said individual is not within said set of haplogroups native to said geographic region.

96. The method of claim 95 wherein said physiological condition is selected from the group consisting of energetic imbalance, metabolic disease, abnormal energy metabolism, abnormal temperature regulation, abnormal oxidative phosphorylation, abnormal electron transport, obesity, amount of body fat, diabetes, hypertension, and cardiovascular disease.

97. The method of claim 95 also comprising associating an amino acid allele with said physiological condition, said method comprising selecting an amino acid allele useful for diagnosing said haplogroup of said individual, wherein the presence of said amino acid allele is not useful for diagnosing one or more haplogroups in said set of haplogroups native to said geographical region in which said individual resides.

98. The method of claim 97 wherein said haplogroup is selected from the group consisting of:

a) haplogroup C and the amino acid allele is selected from the group consisting of ntl 8584 T and ntl 14318 S;

b) haplogroup D and the amino acid allele is selected from the group consisting of ntl 5178 M and ntl 8414F;

c) haplogroup G and the amino acid allele is selected from the group consisting of ntl 4833 A, ntl 8701 T, ntl 13708 T, and ntl 15452 I;

d) haplogroup L0 and the amino acid allele is selected from the group consisting of ntl 5442 L, ntl 7146 A, ntl 9402 P, ntl 13105 V, and ntl 13276 V;

e) haplogroup L1 and the amino acid allele is selected from the group consisting of ntl 7146 A, ntl 7389 H, ntl 13105 V, ntl 13789 H, and ntl 14178 V;

f) haplogroup T and the amino acid allele is selected from the group consisting of ntl 4917 D, ntl 8701 T, and ntl 15452 I;

g) haplogroup W and the amino acid allele is selected from the group consisting of ntl 5046 I, ntl 5460 T, ntl 8701 T, and ntl 15884 P; and

h) haplogroups V and H and the amino acid allele is selected from the group consisting of ntl 8701 T and ntl 14766 T.

99. The method of claim 97 wherein said haplogroup is selected from the group consisting of haplogroups A, I, X, B, F, Y, and U and the amino acid allele is ntl 8701 T.

100. A program storage device in which the steps of claim 95 are encoded in machine-readable form, said device also comprising a storage medium encoding said information identifying the geographic region in which said individual resides and a set of haplogroups native to said geographic region in machine readable form.

101. A storage device comprising a data set encoded in machine-readable form comprising nucleotide alleles selected from the group consisting of evolutionarily significant human mitochondrial nucleotide alleles, each said allele being associated in said storage device with encoded information identifying a physiological condition in humans.

102. The storage device of claim 101 wherein said physiological condition is selected from the group consisting of energetic imbalance, metabolic disease, abnormal energy metabolism, abnormal temperature regulation, abnormal oxidative phosphorylation, abnormal electron transport, obesity, amount of body fat, diabetes, hypertension, and cardiovascular disease.

103. The storage device of claim 101 also comprising encoded information associating each said nucleotide allele with a native geographic region.

104. A program storage device comprising the storage device of claim 101 and also comprising input means for inputting a haplogroup of an individual and a geographic region of said individual, said device further comprising program steps for diagnosing said individual as having a predisposition to a physiological condition.

105. A method for diagnosing a predisposition to LHON in a human comprising:

a) providing a sample from said human;

b) identifying in said sample nucleotide allele 10663C; and

c) identifying in said sample, nucleotide alleles encoding threonine at amino acid position 458 of gene ND5;

wherein the presence of said nucleotide alleles is diagnostic of a predisposition to LHON.

106. A method for diagnosing a predisposition to LHON in a human comprising:

a) providing a sample from said human;

b) identifying in said sample nucleotide allele 10663C; and

c) identifying in said sample at least one nucleotide allele selected

from the group consisting of 295T, 12612G, 13708A, and 16069T, wherein the presence of said nucleotide alleles is diagnostic of a predisposition to LHON.

107. A method for diagnosing a predisposition to LHON in a human comprising:

a) providing a sample from said human; and

b) identifying in said sample a nucleotide allele selected from the group consisting of 3635A and 4640C,

wherein the presence of said nucleotide alleles is diagnostic of a predisposition to LHON.

108. A method for diagnosing increased likelihood of developing blindness in a human comprising:

a) providing a sample from said human;

b) identifying in said sample a nucleotide allele selected from the group consisting of 11778A, 14484C and 10663C; and

c) identifying in said sample, nucleotide alleles encoding threonine at amino acid position 458 of gene ND5,

wherein the presence of said nucleotide alleles is diagnostic of a predisposition to develop blindness.

109. A nucleic acid array comprising two or more spots, each spot comprising a plurality of substantially identical isolated nucleic acid molecules attached to a substrate at a defined location, each molecule having a length of about 7 to about 30 nucleotides, and each molecule comprising a sequence identical with a portion of SEQ ID NO:

1 containing at least one nucleotide allele at a locus selected from the group of loci consisting of those listed in column 1 of Table 3.

110. The array of claim 109 wherein at least one molecule has a sequence comprising a nucleotide allele selected from the group consisting of non-Cambridge human mtDNA nucleotide alleles of Table 3.

111. The array of claim 109 wherein at least one molecule has a sequence comprising a nucleotide allele selected from the group consisting of non-Cambridge human mtDNA nucleotide alleles of Table 4.

112. The array of claim 109 wherein at least one molecule has a sequence comprising a nucleotide allele selected from the group consisting of nucleotide alleles in nucleotide alleles useful for diagnosing human haplogroups and macro-haplogroups (Table 11).

113. The array of claim 109 comprising more than about twenty-five spots.

114. The array of claim 109 wherein said isolated nucleic acid molecules are about 20 nucleotides in length.

115. A method for determining the presence or absence of a nucleotide allele in a sample comprising:

a) providing a prepared human sample;

b) providing an array of claim 109;

c) contacting said array with and said sample under conditions allowing quantitative hybridization;

d) measuring the pattern hybridization of said sample to said array; and

e) analyzing said hybridization.

116. A program storage device comprising:

a) a machine readable storage device comprising a data set encoded in machine readable form, said data set comprising a plurality of nucleotide alleles and a haplogroup designation associated with each allele; and

b) input means for inputting a data set comprising one or more nucleotide alleles, said program storage device also comprising program steps for diagnosing a haplogroup by associating said input nucleotide alleles with an associated haplogroup, and displaying the result.